Loading
After chemoimmunotherapy, combinations of additional drugs were common when cancer remained at surgery. This study describes safety, not whether the combinations improve survival.
Brazilian/Argentinian real-world TNBC cohort: 726 included, 692 underwent surgery and safety information was available for 359. Among residual-disease participants without germline BRCA1/2 mutations, most received pembrolizumab/capecitabine; among the small BRCA-mutated residual group, pembrolizumab/olaparib was common. No survival outcomes are reported.
Observational prescribing/safety data do not establish efficacy, comparative benefit or safety after prior pneumonitis.
Shares PARP, Olaparib, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Olaparib, Breast cancer (all types).
Shares PARP, Olaparib, Breast cancer (all types).
Shares PARP, Olaparib, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Olaparib, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Capecitabine, Triple-negative breast cancer (TNBC), Pembrolizumab.
Shares Olaparib, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Olaparib, Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/